Perceptions and Prescribing Patterns of GSK’s Benlysta and Aurinia’s Lupkynis Highlight an Increasing Divide Among Nephrologists and Rheumatologists, Spherix Finds
Approaching one year on the market to treat lupus nephritis, comprehensive launch coverage reveals a widening gap in attitudes and use of the two new products EXTON, Pa., December 14, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus,[1] and as […]
Could Opportunity for Takeda’s Subcutaneous Entyvio Diminish by the Time It Reaches Its Now Projected 2023 US Approval? Spherix Investigates
Another year of missed opportunity will pass by while other pipeline agents launch, uptake of BMS’ Zeposia potentially picks up, and the controversy surrounding JAK inhibitors unfolds EXTON, Pa., December 7, 2021 /PRNewswire – In their most recent earnings call on October 29, 2021, Takeda revealed that discussions with the FDA have led to a […]
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by […]
A Profile of New Start IBD Patients on Multiple Advanced/Biologic Therapies
Author: Eric John BACKGROUND: After analyzing patient chart data from nearly 1,000 recently-initiated biologic/JAK inhibitor inflammatory bowel disease (IBD) patients, it was discovered that 6% are treated with multiple advanced/biologic therapies. This analysis sought to profile those new start patients on a multi-biologic/JAK inhibitor regimen against those treated with a single advanced therapy to […]
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., December 8, 2021 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
More Than 2,000 Patient Chart Records Reveal Shifting Tides in Kidney Patient Care
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim [Jardiance] and Merck [Steglatro]) EXTON, Pa., / December 7, 2021/ PRNewswire – Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as hyperphosphatemia, secondary hyperparathyroidism (SHPT), […]
EMD Serono’s Mavenclad and Novartis’ Kesimpta Emerging as Growth Brands After Eventful 2021 for the Multiple Sclerosis Market in Canada
Content Area
Physician Hesitation to Prescribe Biogen/Eisai’s Aduhelm in Alzheimer’s Disease Grows Amid Controversies
As brand satisfaction and patient candidacy numbers continue to erode, Spherix will assess the impact of the recent patient death potentially linked to Aduhelm EXTON, Pa., December 1, 2021 /PRNewswire/ — For those of us following the evolution of neurology pharmaceutical markets, 2021 will be remembered by many for the tumultuous roll out of Biogen/Eisai’s Aduhelm (aducanumab) […]
Will Use of AbbVie’s Humira and Future Biosimilars in the US Inflammatory Bowel Disease Market Mirror the Current European Treatment Landscape?
Content Area
Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc’s/Astellas Pharma’s EVRENZO (Roxadustat), Spherix Global Insights Reports
Content Area
